What is VRCA's market cap?

$59.35M, based on the Nov 4 close of $3.46.

Does Verrica Pharmaceuticals pay a dividend?

No regular cash dividend has been paid in the last year.

How much of VRCA is sold short?

192.6K shares, 2.5% of float, as of Oct 15, 2026.

What sector is VRCA in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · VRCAHealthcarePharmaceuticals

Verrica Pharmaceuticals Inc. Common Stock (VRCA)

$3.46+5.02%

Close Nov 4, 2026 · split-adjusted

Nov 2, 2026$3.21▼ 9.83% in range

Nov 3, 2025Low $3.21 · High $9.10Nov 2, 2026

What changed · written from our data

As of Nov 4, 2026

Verrica Pharmaceuticals closed at $3.46 on Nov 4, up 5.02%, 62.0% below its 52-week closing high. Volume of 31.2K shares was 0.57× its 20-day average (below normal).

Split-adjusted performance: -17.9% over one month, -59.0% over six months, -2.9% over one year.

In the quarter ended Jun 30, 2026, revenue was $5.86M, down 53.8% from a year earlier, with a net margin of -224.4%.

Short interest was 192.6K shares at the Oct 15 settlement, down 1.8% from the prior report (2.5% of float, 3.8 days to cover).

Market cap$59.4M17.2M shares

Revenue · quarter$5.9M−53.8% YoY

Diluted EPS$-0.62−3200.0% YoY

P/E · TTM—P/S 2.0×

Net margin-224.4%Gross 85.0%

Dividend yieldNone

52-week range3.21 – 9.10−62.0% from high

Volume31.2K0.57× 20-day avg

Volatility · 60d63.6%Annualised

Short % of float2.5%3.8 days to cover

Net cash$9.8MCash $11.2M

Next earnings—Not scheduled

Split-adjusted performance

1W −0.7%1M −17.9%3M −35.5%6M −59.0%YTD −58.4%1Y −2.9%3Y −90.2%5Y −97.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum19

Revenue growth21

Net margin36

Value (low P/E)—

Size34

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short192.6K−1.8% vs prior

Days to cover3.8Settled Oct 15

% of float2.5%

Short vol. 10d44.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
VRCAVerrica Pharmaceuticals	$3.46	+5.02%	−59.0%	−53.8%	−224.4%	—	$59.4M
XBITXBiotech	$1.95	−2.01%	−23.5%	—	—	—	$59.5M	Compare
RNXTRenovoRx	$1.31	+1.55%	+47.2%	+115.4%	−320.2%	—	$59.1M	Compare
CLNNClene	$4.10	+8.75%	−42.7%	+233.3%	−14915.6%	—	$58.3M	Compare
NMADNomad Power Solutions	$3.60	+2.27%	—	—	—	—	$58.0M	Compare
GOSSGossamer Bio	$9.95	+7.22%	−64.5%	−19.6%	182.9%	—	$60.9M	Compare
CTORCitius Oncology	$0.5470	−0.55%	−39.8%	—	−597.4%	—	$57.9M	Compare
XLOXilio Therapeutics	$8.71	+0.35%	+10.3%	+131.2%	−34.1%	—	$57.3M	Compare
RNTXRein Therapeutics	$0.6587	−1.32%	−43.7%	—	—	—	$56.8M	Compare

News about Verrica Pharmaceuticals

All news →

No recent articles focused on Verrica Pharmaceuticals.

Quick answers

What does Verrica Pharmaceuticals do?: Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.
What is VRCA's market cap?: $59.35M, based on the Nov 4 close of $3.46.
Does Verrica Pharmaceuticals pay a dividend?: No regular cash dividend has been paid in the last year.
How much of VRCA is sold short?: 192.6K shares, 2.5% of float, as of Oct 15, 2026.
What sector is VRCA in?: Healthcare, in the Pharmaceuticals industry.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

HQ: West Chester, PA76 employeesListed Jun 15, 2018verrica.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology